AptaBio Therapeutics Inc. (KOSDAQ:293780)
South Korea · Delayed Price · Currency is KRW 6,460.00
-160.00 (-2.42%)
Sep 4, 2026, 3:30 PM KST
AptaBio Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Operating Revenue | 4,753 | 3,698 | 3,361 | 323.87 | 48.35 |
Other Revenue | -0 | -0 | - | - | - |
| 4,753 | 3,698 | 3,361 | 323.87 | 48.35 | |
Revenue Growth | 52.91% | 10.03% | 937.76% | 569.80% | - |
Cost of Revenue | 2,509 | 2,409 | 3,087 | 262.8 | 11.15 |
Gross Profit | 2,244 | 1,289 | 273.69 | 61.06 | 37.21 |
Selling, General & Admin | 6,278 | 5,569 | 3,893 | 3,385 | 2,788 |
Research & Development | 13,763 | 10,501 | 14,591 | 12,380 | 6,197 |
Amortization of Goodwill & Intangibles | 7.96 | 11.79 | 21.73 | 23.34 | 14.53 |
Other Operating Expenses | 161.47 | 199.64 | 113.05 | 130.03 | 74.48 |
Operating Expenses | 20,996 | 16,825 | 20,989 | 16,965 | 9,544 |
Operating Income | -18,752 | -15,536 | -20,715 | -16,904 | -9,507 |
Interest Expense | -1,700 | -2,118 | -3,401 | -1,183 | -4.49 |
Interest & Investment Income | 974.24 | 1,265 | 2,296 | 1,984 | 1,572 |
Earnings From Equity Investments | 1,270 | -2,653 | -625.93 | -4.19 | - |
Currency Exchange Gain (Loss) | -71.02 | 40.15 | -252.8 | -29.52 | -14.43 |
Other Non Operating Income (Expenses) | 5,580 | 3,812 | -4,651 | 1,688 | 42.49 |
EBT Excluding Unusual Items | -12,699 | -15,190 | -27,350 | -14,448 | -7,911 |
Impairment of Goodwill | -475.11 | -475.11 | - | - | - |
Gain (Loss) on Sale of Investments | -688.76 | 324.71 | -452.59 | -244.29 | -2,654 |
Pretax Income | -13,863 | -15,340 | -27,803 | -14,692 | -10,565 |
Income Tax Expense | 1,006 | 1,006 | 1,575 | -2,630 | - |
Net Income | -14,869 | -16,346 | -29,378 | -12,062 | -10,565 |
Preferred Dividends & Other Adjustments | - | - | - | -195.14 | - |
Net Income to Common | -14,869 | -16,346 | -29,378 | -11,866 | -10,565 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 27 | 27 | 24 | 22 | 22 |
Shares Outstanding (Diluted) | 27 | 27 | 24 | 22 | 22 |
Shares Change | 11.67% | 14.31% | 5.57% | 0.05% | - |
EPS (Basic) | -541.07 | -607.49 | -1248.00 | -532.16 | -474.00 |
EPS (Diluted) | -541.07 | -607.49 | -1248.00 | -532.16 | -474.00 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -17,404 | -15,335 | -12,400 | -15,440 | -7,874 |
Free Cash Flow Per Share | -633.29 | -569.90 | -526.76 | -692.42 | -353.27 |
Gross Margin | 47.21% | 34.84% | 8.14% | 18.86% | 76.95% |
Operating Margin | -394.53% | -420.14% | -616.35% | -5219.25% | -19661.23% |
Profit Margin | -312.83% | -442.04% | -874.09% | -3663.98% | -21849.26% |
Free Cash Flow Margin | -366.15% | -414.69% | -368.94% | -4767.39% | -16284.04% |
EBITDA | -18,317 | -15,056 | -20,184 | -16,364 | -9,022 |
D&A For EBITDA | 435.38 | 480.81 | 531.35 | 539.11 | 484.62 |
EBIT | -18,752 | -15,536 | -20,715 | -16,904 | -9,507 |
Advertising Expenses | - | 647.07 | 9 | 3 | 7.07 |